{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T10:24:51Z","timestamp":1781778291571,"version":"3.54.5"},"reference-count":68,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","europeanneuropsychopharmacology.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.euroneuro.2016.12.006","type":"journal-article","created":{"date-parts":[[2017,1,5]],"date-time":"2017-01-05T17:02:18Z","timestamp":1483635738000},"page":"107-119","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Semi-mechanistic computer simulation of psychotic symptoms in schizophrenia with a model of a humanized cortico-striatal-thalamocortical loop"],"prefix":"10.1016","volume":"27","author":[{"given":"Athan","family":"Spiros","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9736-1800","authenticated-orcid":false,"given":"Hugo","family":"Geerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.euroneuro.2016.12.006_bib1","doi-asserted-by":"crossref","first-page":"8104","DOI":"10.1073\/pnas.97.14.8104","article-title":"Increased baseline occupancy of D2 receptors by dopamine in schizophrenia","volume":"97","author":"Abi-Dargham","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.euroneuro.2016.12.006_bib2","first-page":"53","article-title":"A quantitative way to estimate clinical off-target effects for human membrane brain targets in CNS research and development","volume":"4","author":"Athan Spiros","year":"2012","journal-title":"J. Exp. Pharmacol."},{"issue":"4","key":"10.1016\/j.euroneuro.2016.12.006_bib3","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1177\/2045125315588647","article-title":"Concomitant use of two or more antipsychotic drugs is common in Sweden","volume":"5","author":"Bergendal","year":"2015","journal-title":"Ther. Adv. Psychopharmacol."},{"issue":"7428","key":"10.1016\/j.euroneuro.2016.12.006_bib4","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nature11691","article-title":"Automated design of ligands to polypharmacological profiles","volume":"492","author":"Besnard","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.euroneuro.2016.12.006_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpsycho.2016.05.003","article-title":"Conscious brain, metacognition and schizophrenia","volume":"105","author":"Bob","year":"2016","journal-title":"Int. J. Psychophysiol.: Off. J. Int. Organ. Psychophysiol."},{"issue":"1","key":"10.1016\/j.euroneuro.2016.12.006_bib6","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1124\/jpet.111.188417","article-title":"Prediction of human serotonin and norepinephrine transporter occupancy of duloxetine by pharmacokinetic\/pharmacodynamic modeling in the rat","volume":"341","author":"Bourdet","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/j.euroneuro.2016.12.006_bib7","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1080\/10401230600614678","article-title":"Aripiprazole and haloperidol: a clinically relevant interaction with a dopamine antagonist and partial agonist","volume":"18","author":"Burke","year":"2006","journal-title":"Ann. Clin. psychiatry: Off. J. Am. Acad. Clin. Psychiatr."},{"issue":"1","key":"10.1016\/j.euroneuro.2016.12.006_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13408-015-0034-5","article-title":"Wilson-Cowan for neocortical dynamics","volume":"6","author":"Cowan","year":"2016","journal-title":"J. Math. Neurosci."},{"issue":"4\u20136","key":"10.1016\/j.euroneuro.2016.12.006_bib9","first-page":"365","article-title":"Glutamate and schizophrenia: beyond the dopamine hypothesis","volume":"26","author":"Coyle","year":"2006","journal-title":"Cell Mol. Neurobiol."},{"issue":"4","key":"10.1016\/j.euroneuro.2016.12.006_bib10","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1038\/npp.2011.295","article-title":"Glycine transporter inhibitor attenuates the psychotomimetic effects of ketamine in healthy males: preliminary evidence","volume":"37","author":"D\u05f3Souza","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2016.12.006_bib11","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1186\/s12888-014-0341-5","article-title":"Antipsychotic patterns of use in patients with schizophrenia: polypharmacy versus monotherapy","volume":"14","author":"Fisher","year":"2014","journal-title":"BMC Psychiatry"},{"issue":"1","key":"10.1016\/j.euroneuro.2016.12.006_bib12","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/schbul\/sbr111","article-title":"Striatal presynaptic dopamine in schizophrenia, Part I: meta-analysis of dopamine active transporter (DAT) density","volume":"39","author":"Fusar-Poli","year":"2013","journal-title":"Schizophr. Bull."},{"issue":"1","key":"10.1016\/j.euroneuro.2016.12.006_bib13","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/schbul\/sbr180","article-title":"Striatal presynaptic dopamine in schizophrenia, part II: meta-analysis of [(18)F\/(11)C]-DOPA PET studies","volume":"39","author":"Fusar-Poli","year":"2013","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2016.12.006_bib14","doi-asserted-by":"crossref","DOI":"10.1517\/14740338.2016.1165668","article-title":"Safety and tolerability of antipsychotic co-treatment in patients with schizophrenia: results from a systematic review and meta-analysis of randomized controlled trials","author":"Galling","year":"2016","journal-title":"Expert Opin. Drug Saf."},{"issue":"11","key":"10.1016\/j.euroneuro.2016.12.006_bib15","doi-asserted-by":"crossref","first-page":"915","DOI":"10.2165\/11310890-000000000-00000","article-title":"Of mice and men: bridging the translational disconnect in CNS drug discovery","volume":"23","author":"Geerts","year":"2009","journal-title":"CNS Drugs"},{"issue":"16","key":"10.1016\/j.euroneuro.2016.12.006_bib16","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.4155\/fmc.14.97","article-title":"Multitarget drug discovery projects in CNS diseases: quantitative systems pharmacology as a possible path forward","volume":"6","author":"Geerts","year":"2014","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.euroneuro.2016.12.006_bib17","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.1038\/psp.2013.12","article-title":"A quantitative system pharmacology computer model for cognitive deficits in schizophrenia","volume":"2","author":"Geerts","year":"2013","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"issue":"4","key":"10.1016\/j.euroneuro.2016.12.006_bib18","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1177\/0269881114568042","article-title":"Understanding responder neurobiology in schizophrenia using a quantitative systems pharmacology model: application to iloperidone","volume":"29","author":"Geerts","year":"2015","journal-title":"J. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.euroneuro.2016.12.006_bib19","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s10928-013-9297-1","article-title":"Quantitative systems pharmacology as an extension of PK\/PD modeling in CNS research and development","volume":"40","author":"Geerts","year":"2013","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"issue":"12","key":"10.1016\/j.euroneuro.2016.12.006_bib20","doi-asserted-by":"crossref","first-page":"e49732","DOI":"10.1371\/journal.pone.0049732","article-title":"Blinded prospective evaluation of computer-based mechanistic schizophrenia disease model for predicting drug response","volume":"7","author":"Geerts","year":"2012","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.euroneuro.2016.12.006_bib21","doi-asserted-by":"crossref","first-page":"7","DOI":"10.31887\/DCNS.2016.18.1\/shaber","article-title":"Corticostriatal circuitry","volume":"18","author":"Haber","year":"2016","journal-title":"Dialog. Clin. Neurosci."},{"issue":"3","key":"10.1016\/j.euroneuro.2016.12.006_bib22","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/nn.4238","article-title":"Computational psychiatry as a bridge from neuroscience to clinical applications","volume":"19","author":"Huys","year":"2016","journal-title":"Nat. Neurosci."},{"issue":"6176","key":"10.1016\/j.euroneuro.2016.12.006_bib23","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1126\/science.1252603","article-title":"Time for new schizophrenia Rx","volume":"343","author":"Hyman","year":"2014","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.euroneuro.2016.12.006_bib24","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1177\/1039856214546672","article-title":"Prevalence and nature of antipsychotic polypharmacy among inpatients with schizophrenia spectrum disorders at an Australian mental health service","volume":"22","author":"John","year":"2014","journal-title":"Australas. Psychiatry: Bull. R. Aust. New Zealand Coll. Psychiatr."},{"issue":"5","key":"10.1016\/j.euroneuro.2016.12.006_bib25","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/WNF.0b013e31819a68b5","article-title":"Effectiveness of switching to aripiprazole from atypical antipsychotics in patients with schizophrenia","volume":"32","author":"Kim","year":"2009","journal-title":"Clin. Neuropharmacol."},{"issue":"11","key":"10.1016\/j.euroneuro.2016.12.006_bib26","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.biopsych.2015.03.016","article-title":"Exploratory analysis for a targeted patient population responsive to the metabotropic glutamate 2\/3 receptor agonist pomaglumetad methionil in schizophrenia","volume":"78","author":"Kinon","year":"2015","journal-title":"Biol. Psychiatry"},{"issue":"9","key":"10.1016\/j.euroneuro.2016.12.006_bib27","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1523\/JNEUROSCI.3703-08.2009","article-title":"Mg2+ imparts NMDA receptor subtype selectivity to the Alzheimer\u05f3s drug memantine","volume":"29","author":"Kotermanski","year":"2009","journal-title":"J. Neurosci."},{"issue":"9","key":"10.1016\/j.euroneuro.2016.12.006_bib28","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1038\/nn.3181","article-title":"HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity","volume":"15","author":"Kurita","year":"2012","journal-title":"Nat. Neurosci."},{"issue":"1","key":"10.1016\/j.euroneuro.2016.12.006_bib29","doi-asserted-by":"crossref","DOI":"10.1007\/s00213-003-1673-x","article-title":"Selective alterations in prefrontal cortical GABA neurotransmission in schizophrenia: a novel target for the treatment of working memory dysfunction","author":"Lewis","year":"2003","journal-title":"Psychopharmacology"},{"issue":"3","key":"10.1016\/j.euroneuro.2016.12.006_bib30","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/ana.23951","article-title":"Adaptive deep brain stimulation in advanced Parkinson disease","volume":"74","author":"Little","year":"2013","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.euroneuro.2016.12.006_bib31","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1038\/psp.2014.7","article-title":"Prediction of efficacy of vabicaserin, a 5-HT2C agonist, for the treatment of schizophrenia using a quantitative systems pharmacology model","volume":"3","author":"Liu","year":"2014","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"issue":"5","key":"10.1016\/j.euroneuro.2016.12.006_bib32","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1097\/JCP.0b013e31814f4d5d","article-title":"Resolution of haloperidol-induced hyperprolactinemia with aripiprazole","volume":"27","author":"Lorenz","year":"2007","journal-title":"J. Clin. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.euroneuro.2016.12.006_bib33","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.cell.2015.09.029","article-title":"Reconstruction and simulation of neocortical microcircuitry","volume":"163","author":"Markram","year":"2015","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.euroneuro.2016.12.006_bib34","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/nn804","article-title":"Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia","volume":"5","author":"Meyer-Lindenberg","year":"2002","journal-title":"Nat. Neurosci."},{"issue":"3","key":"10.1016\/j.euroneuro.2016.12.006_bib35","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1124\/mol.106.025130","article-title":"Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors","volume":"70","author":"Mihalak","year":"2006","journal-title":"Mol. Pharmacol."},{"issue":"3","key":"10.1016\/j.euroneuro.2016.12.006_bib36","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.tins.2014.12.005","article-title":"Translating the MAM model of psychosis to humans","volume":"38","author":"Modinos","year":"2015","journal-title":"Trends Neurosci."},{"issue":"3","key":"10.1016\/j.euroneuro.2016.12.006_bib37","doi-asserted-by":"crossref","first-page":"83","DOI":"10.4236\/aad.2013.23012","article-title":"Systems pharmacology modeling in neuroscience: prediction and outcome of PF-04995274, a 5HT4 partial agonist, in a clinical scopolamine impairment trial","volume":"2","author":"Nicholas","year":"2013","journal-title":"Adv. Alzheimer\u05f3s Dis."},{"issue":"12","key":"10.1016\/j.euroneuro.2016.12.006_bib38","doi-asserted-by":"crossref","first-page":"30144","DOI":"10.3390\/ijms161226228","article-title":"Alterations of dopamine D2 receptors and related receptor-interacting proteins in schizophrenia: the pivotal position of dopamine supersensitivity psychosis in treatment-resistant schizophrenia","volume":"16","author":"Oda","year":"2015","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.euroneuro.2016.12.006_bib39","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.biosystems.2011.03.005","article-title":"Efficiency of neural transmission as a function of synaptic noise, threshold, and source characteristics","volume":"105","author":"Paprocki","year":"2011","journal-title":"Biosystems"},{"issue":"3","key":"10.1016\/j.euroneuro.2016.12.006_bib40","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.neuroimage.2008.02.065","article-title":"Imaging dopamine release with Positron Emission Tomography (PET) and (11)C-raclopride in freely moving animals","volume":"41","author":"Patel","year":"2008","journal-title":"NeuroImage"},{"key":"10.1016\/j.euroneuro.2016.12.006_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbagen.2016.04.031","article-title":"A heuristic model for working memory deficit in schizophrenia","author":"Qi","year":"2016","journal-title":"Biochim. et Biophys. Acta"},{"key":"10.1016\/j.euroneuro.2016.12.006_bib42","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3389\/fphar.2016.00006","article-title":"A Humanized clinically calibrated quantitative systems pharmacology model for hypokinetic motor symptoms in Parkinson\u05f3s disease","volume":"7","author":"Roberts","year":"2016","journal-title":"Front. Pharmacol."},{"issue":"6","key":"10.1016\/j.euroneuro.2016.12.006_bib43","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/alzrt153","article-title":"Simulations of symptomatic treatments for Alzheimer\u05f3s disease: computational analysis of pathology and mechanisms of drug action","volume":"4","author":"Roberts","year":"2012","journal-title":"Alzheimers Res. Ther."},{"issue":"10","key":"10.1016\/j.euroneuro.2016.12.006_bib44","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyv042","article-title":"Biomarkers for psychiatry: the journey from fantasy to fact, a report of the 2013 CINP think tank","volume":"18","author":"Scarr","year":"2015","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.euroneuro.2016.12.006_bib45","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0022-3565(24)29296-X","article-title":"Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system","volume":"299","author":"Schoepp","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/j.euroneuro.2016.12.006_bib46","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1755-5949.2010.00162.x","article-title":"All roads to schizophrenia lead to dopamine supersensitivity and elevated dopamine D2 (high) receptors","volume":"17","author":"Seeman","year":"2011","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.euroneuro.2016.12.006_bib47","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/j.1538-7305.1948.tb00917.x","article-title":"The mathematical theory of communication","volume":"27","author":"Shannon","year":"1948","journal-title":"Bell Syst. Tech. J."},{"issue":"1","key":"10.1016\/j.euroneuro.2016.12.006_bib48","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1523\/JNEUROSCI.4637-10.2011","article-title":"Information capacity and transmission are maximized in balanced cortical networks with neuronal avalanches","volume":"31","author":"Shew","year":"2011","journal-title":"J. Neurosci."},{"issue":"9","key":"10.1016\/j.euroneuro.2016.12.006_bib49","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1176\/appi.ajp.2007.06071075","article-title":"Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial","volume":"164","author":"Shim","year":"2007","journal-title":"Am. J. Psychiatry"},{"issue":"15","key":"10.1016\/j.euroneuro.2016.12.006_bib50","doi-asserted-by":"crossref","first-page":"5022","DOI":"10.1523\/JNEUROSCI.5187-08.2009","article-title":"The structure of large-scale synchronized firing in primate retina","volume":"29","author":"Shlens","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.euroneuro.2016.12.006_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2015.09.014","article-title":"Computational modeling of psychiatric illnesses via well-defined neurophysiological and neurocognitive biomarkers","author":"Siekmeier","year":"2015","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.euroneuro.2016.12.006_bib52","first-page":"589","article-title":"Not all partial dopamine D(2) receptor agonists are the same in treating schizophrenia. Exploring the effects of bifeprunox and aripiprazole using a computer model of a primate striatal dopaminergic synapse","volume":"6","author":"Spiros","year":"2010","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"4","key":"10.1016\/j.euroneuro.2016.12.006_bib53","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/ddr.21008","article-title":"A quantitative systems pharmacology computer model for schizophrenia efficacy and extrapyramidal side effects","volume":"73","author":"Spiros","year":"2012","journal-title":"Drug Dev. Res."},{"issue":"4","key":"10.1016\/j.euroneuro.2016.12.006_bib54","first-page":"569","article-title":"Phenotypic screening of the Prestwick library for treatment of Parkinson\u05f3s tremor symptoms using a humanized quantitative systems pharmacology platform","volume":"3","author":"Spiros","year":"2013","journal-title":"J. Park. Dis."},{"key":"10.1016\/j.euroneuro.2016.12.006_bib55","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3389\/fphar.2014.00229","article-title":"A computer-based quantitative systems pharmacology model of negative symptoms in schizophrenia: exploring glycine modulation of excitation-inhibition balance","volume":"5","author":"Spiros","year":"2014","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.euroneuro.2016.12.006_bib56","first-page":"621","article-title":"On the application of information theory to neural spike trains","author":"Strong","year":"1998","journal-title":"Pac. Symp. Biocomput."},{"issue":"1","key":"10.1016\/j.euroneuro.2016.12.006_bib57","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.psychres.2015.03.019","article-title":"Optimization of psychopharmacotherapy for schizophrenia in a male, locked, non-acute unit serving for persistently ill patients over one year","volume":"228","author":"Suzuki","year":"2015","journal-title":"Psychiatry Res."},{"issue":"2","key":"10.1016\/j.euroneuro.2016.12.006_bib58","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1088\/0954-898X_14_2_309","article-title":"Application of Lempel\u2013Ziv complexity to the analysis of neural discharges","volume":"14","author":"Szczepanski","year":"2003","journal-title":"Network"},{"issue":"4","key":"10.1016\/j.euroneuro.2016.12.006_bib59","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1177\/0269881115570083","article-title":"Dopamine supersensitivity psychosis and dopamine partial agonist: a retrospective survey of failure of switching to aripiprazole in schizophrenia","volume":"29","author":"Takase","year":"2015","journal-title":"J. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.euroneuro.2016.12.006_bib60","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s00213-013-3154-1","article-title":"A systematic review of reported cases involving psychotic symptoms worsened by aripiprazole in schizophrenia or schizoaffective disorder","volume":"228","author":"Takeuchi","year":"2013","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1016\/j.euroneuro.2016.12.006_bib62","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1523\/JNEUROSCI.3359-07.2008","article-title":"A maximum entropy model applied to spatial and temporal correlations from cortical networks in vitro","volume":"28","author":"Tang","year":"2008","journal-title":"J. Neurosci."},{"issue":"37","key":"10.1016\/j.euroneuro.2016.12.006_bib63","doi-asserted-by":"crossref","first-page":"11508","DOI":"10.1073\/pnas.1514188112","article-title":"Thermodynamics and signatures of criticality in a network of neurons","volume":"112","author":"Tkacik","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"2","key":"10.1016\/j.euroneuro.2016.12.006_bib64","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1176\/appi.ps.201300085","article-title":"Outcomes of medicaid beneficiaries with schizophrenia receiving clozapine only or antipsychotic combinations","volume":"66","author":"Velligan","year":"2015","journal-title":"Psychiatr. Serv."},{"issue":"3","key":"10.1016\/j.euroneuro.2016.12.006_bib65","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.neuron.2014.10.018","article-title":"Computational psychiatry","volume":"84","author":"Wang","year":"2014","journal-title":"Neuron"},{"issue":"3","key":"10.1016\/j.euroneuro.2016.12.006_bib66","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1176\/appi.ajp.161.3.490","article-title":"Prefrontal broadband noise, working memory, and genetic risk for schizophrenia","volume":"161","author":"Winterer","year":"2004","journal-title":"Am. J. Psychiatry"},{"issue":"7\u20138","key":"10.1016\/j.euroneuro.2016.12.006_bib67","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1345\/aph.1Q700","article-title":"Strategies for transitioning therapy to aripiprazole from other antipsychotics in schizophrenia","volume":"46","author":"Wisniewski","year":"2012","journal-title":"Ann. Pharmacother."},{"issue":"5","key":"10.1016\/j.euroneuro.2016.12.006_bib68","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyu016","article-title":"Evaluation of the individual safe correction of antipsychotic agent polypharmacy in Japanese patients with chronic schizophrenia: validation of safe corrections for antipsychotic polypharmacy and the high-dose method","volume":"18","author":"Yamanouchi","year":"2015","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2016.12.006_bib69","doi-asserted-by":"crossref","unstructured":"Yazicioglu, F., Lopez, C.M., et al., 2014. Ultra-high-density in-vivo neural probes. Conference Proceedings: Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference 2014, pp. 2032\u20132035.","DOI":"10.1109\/EMBC.2014.6944015"}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X16320144?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X16320144?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T01:19:34Z","timestamp":1749863974000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X16320144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":68,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["S0924977X16320144"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2016.12.006","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Semi-mechanistic computer simulation of psychotic symptoms in schizophrenia with a model of a humanized cortico-striatal-thalamocortical loop","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2016.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. and ECNP. All rights reserved.","name":"copyright","label":"Copyright"}]}}